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Central neuropathic pain is diﬃcult to treat, but delta 9-Tetrahydrocannabinol (delta 9-THC) may be a promising therapeutic
agent. We administered in 172 patients on average 7.5 mg delta 9-THC over 7 months. Of these, 48 patients prematurely withdrew
d u et os i d ee ﬀects, insuﬃcient analgesia, or expense of therapy. Thus, 124 patients were assessed retrospectively in a multicenter
telephone survey. Reported changes in pain intensity, recorded on a numeric rating scale (NRS), Pain Disability Index (PDI),
Medical Outcomes Short-Form (SF-12), Quality of Life Impairment by Pain (QLIP), Hospital Anxiety Depression Scale (HADS),
and amount of concomitant pain medication were recorded. Psychometric parameters (PDI, SF-12, QLIP, HADS) and pain
intensity improved signiﬁcantly during delta 9-THC treatment. Opioid doses were reduced and patients perceived THC therapy
as eﬀective with tolerable side eﬀects. About 25% of the patients, however, did not tolerate the treatment. Therapy success and
tolerance can be assessed by a transient delta 9-THC titration and its maintained administration for several weeks. The present
survey demonstrates its ameliorating potential for the treatment of chronic pain in central neuropathy and ﬁbromyalgia. A
supplemental delta 9-THC treatment as part of a broader pain management plan therefore may represent a promising coanalgesic
therapeutic option.
Copyright © 2009 Janet Weber et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Various drugs belonging to diﬀerent pharmacologic classes
are currently prescribed and administered for the treatment
of central neuropathic pain and ﬁbromyalgia syndrome,
including antidepressants, ﬁrst- and second-generation anti-
convulsants, antiarrhythmics, topical agents, N-methyl-D-
aspartate receptor antagonists, and opioid analgesics [1, 2].
The long-term use of these drugs is often limited by adverse
eﬀects or patient’s compliance. About 25% of the patients
consulting pain clinics suﬀer from neuropathic pain states
[3]; however, central neuropathic pain is often refractory to
many treatments.
Over the last decades, the cannabinoids and their chem-
istry, the enzymes and receptors involved in their meta-
bolism, as well as their assumed physiological and pathologi-
cal roles in human pain pathways, have been characterized in
detail [4–8].
Among hundreds of constituents of cannabis sativa, delta
9-Tetrahydrocannabinol (delta 9-THC) is the main active
constituent. It is one of the natural compounds of marijuana
(cannabis, hash) and was ﬁrst synthesized by Mechoulam
in 1967 [9]. The therapeutic use of cannabis has been
widely reviewed [10–14] but the clinical use so far has
been conﬂicting and is limited partly due to the narrow
therapeutic index of delta 9-THC [15]. Several practical
problems as well as ethical issues due to their potential abuse
have been raised; however, delta 9-THC meanwhile is legally
available for medical treatment throughout the world (US,
Europe, Africa). It was reported that THC revealed beneﬁcial2 Anesthesiology Research and Practice
eﬀects on pain and spasticity caused by multiple sclerosis
[16, 17]. Also, THC might be eﬀective in the treatment
of chemotherapy-induced emesis, depression, low appetite,
paresthesia, muscle pain, and painful neuropathy [18, 19],
and cannabidiol represents a promising therapeutic agent
in neurodegenerative disorders [10]. The indication for a
cannabinoid-based therapy, however, demands a thorough
risk/beneﬁt evaluation. Particularly the patients’ history of
substance abuse has to be considered [20], as well as the
speciﬁc diagnosis of the patients disease (e.g., cancer, HIV,
MS, etc.). The eﬃcacy of cannabinoids has been reported to
be controversial in the literature when neuropathic pain [21,
22], experimentally induced pain [23], or hyperalgesia [24]
are concerned. Therefore, delta 9-THC should be classiﬁed
as a coanalgesic [25, 26] rather than pure analgesic drug.
Here, we explored the clinical applicability and eﬃcacy
of delta 9-THC administration supplemental to existing
medication plan of patients suﬀering from refractory central
neuropathic pain and ﬁbromyalgia by means of a standard-
ized retrospective telephone interview survey.
2.MaterialandMethods
After approval by the Ethics Committee II, Medical Faculty
Mannheim,UniversityofHeidelberg,19practitionerswithin
diﬀerent Federal States of Germany recruited 172 patients
diagnosed with central neuropathic pain and ﬁbromyalgia.
The 19 medical specialists were particularly experienced
in anaesthesiology, neurology, and algesiology, as well as
their extensive experience with the therapy of chronic and
neuropathic pain patients. None of the 19 practitioners had
received previously industry sponsored research money or
were in cooperation with the authors. All practitioners had
prescribed THC before and at least 10 times per year and
were members of the German Association for Pain Therapy
(DGS).
Delta 9-THC is available on prescription only. Inclu-
sion criteria for prescription were primarily ineﬀectiveness
of current pain therapy, but also sleep disturbances and
decreasedqualityoflifereportedbythepatients.Fortitration
of the drug, all practitioners increased the oral delta 9-THC
dose weekly by 2.5mg and as long as no severe side eﬀects
were reported. Dosing did not exceed 15mg per day, unless
medication was ineﬀective. Delta 9-THC was taken in the
morningandeveningandtherapywasmaintainedforatleast
3 months. Each medical specialist contributed on average
5–8 patients to the survey, who signed a written informed
consent prior to delta 9-THC medication. Only patients
with a central neuropathic pain syndrome or ﬁbromyalgia
were included, irrespective of gender, age, or ethnic origin.
The existence of central neuropathic pain was deﬁned when
patients suﬀered central neuropathy due to an inﬂammatory
damage or trauma of the central nervous system. Exclusion
criteria were chronic neuropathic pain states of peripheral
origin. All 172 patients received, in addition to their current
medication, delta 9-THC (dronabinol; Delta 9 Pharma,
Neumarkt, Germany) for pain therapy. Demographic data,
general health, diagnosis, and medical history were compiled
from the patients’ ﬁles. A researcher, who was experienced
in performing telephone interviews, but had no association
with the authors or the 19 medical specialists, was employed
to collect the data. The interviewer was not informed about
the medication plan of the patient or the objective of
the survey. Following parameters were recorded: patients’
self-reported pain intensity (verbal and numeric ratings),
eﬃcacy and tolerability of the pre-THC regimen, eﬃcacy
and tolerability of delta 9-THC medication, improvement
in mood and quality of life, general impairment, and work
performance. Eﬃcacy and tolerability of pre-THC regimen
and current analgesic therapy was recorded using a rating
scale in the range from 1 to 6, with the descriptors (1)
“very good,” (2) “good,” (3) “satisfying,” (4) “critical,” (5)
“insuﬃcient,” and (6) “poorly.” Further, a psychometric
assessment was performed, including the Medical Outcomes
Short-Form (SF-12), the Pain Disability Index (PDI), the
Quality of Life Impairment by Pain (QLIP), and the Hospital
Anxiety and Depression Scale (HADS).
The perceived pain intensity was estimated by the
patients on a 6-point Verbal Rating Scale (VRS) with
the particular descriptors (corresponding values given in
brackets): no pain (0), slight pain (2), moderate pain (4),
intense pain (6), very strong pain (8), worst pain imaginable
(10). In addition, maximum pain intensity was estimated
on an 11-point Numeric Rating Scale (NRS) with the
endpoints 0 (no pain) and 10 (maximum pain imaginable).
Also, patients were requested to evaluate possible changes
of symptoms resulting from delta 9-THC treatment. In
particular, characteristics of pain intensity and pain quality,
tolerability of delta 9-THC therapy, and changes in coanal-
gesics were recorded. Patients were instructed to specify side
eﬀects by means of a list of thirty characters. Recordings
made by the patients were documented independently from
the practitioner’s assessment regarding adverse eﬀects and
eﬀectiveness.
Data were analyzed by means of descriptive statistical
analysis using SPSS software package (SPSS Inc., Chicago,
Illinois, USA). Patients’ values prior to delta 9-THC therapy
and values during THC treatment were evaluated for signif-
icant diﬀerences between the values identiﬁed by ANOVA.
In order to analyze categorical data in which P-values
were calculated for c (columns) × r (rows), StatExact 5.0
software package (Cytel Inc., Massachusetts, US) was used
and Pearson’s chi-square test applied (P<. 05). Data of
psychometric assessment are depicted as mean + standard
deviation (SD).
3. Results
Of the 172 patients, 48 prematurely withdrew within 2 weeks
from the survey due to tiredness as side eﬀect (n = 6),
insuﬃcient therapy eﬀect (n = 5), expenses of delta 9-THC
therapy (n = 29), or other reasons (n = 23) that include
mainly dizziness and an enhanced appetite. Consequently,
complete data sets were recorded from 124 patients only (77
women, 47 men, average age 55 ±13 years).
3.1. Demographic Details and Diagnosis. Most of the patients
(n = 114) had been suﬀering from pain for more than threeAnesthesiology Research and Practice 3
Table 1: Etiology of the diagnosed central neuropathic pain.
Neuropathies within the patient cohort were grouped by an
inﬂammatory origin (n = 43) or a trauma of the central nervous
system (n = 49). Note that ﬁbromyalgia patients (n = 32) are not
listed.
Inﬂammatory Central neuropathy
central neuropathy due to trauma
Multiple sclerosis (n = 32) Paraplegia (n = 8)
Encephalitis (n=9) Stroke (n = 10)
Others (n = 2) Intracranial injury (n = 4)
Neoplasm (n = 4)
Others (n = 23)
years, other patients for 1 to 3 years (n = 7). Of 3 patients,
however, no duration of pain history could be obtained.
The etiology of the patients diagnosed with central
neuropathy (n = 92) was primarily of inﬂammatory origin
(n = 43), such as multiple sclerosis (n = 32), encephalitis
(n = 9), and others (n = 2 ) ,o rd u et oat r a u m ao ft h e
central nervous system (n = 49), such as stroke (n = 10),
paraplegia (n = 8), intracranial injury (n = 4), neoplasm
(n = 4), or others (n = 23) (see Table 1). A somatic cause
of pain in neoplasm patients due to the location and extent
of the neoplasm was excluded by ultrasound and computer
tomography examination.
In addition to central neuropathy patients, 32 ﬁbromyal-
gia patients suﬀering also chronic pain were included in
the survey. A controversy is prevailing whether ﬁbromyalgia
patients can be included as a central neuropathic pain state.
It has been reported in former studies that ﬁbromyalgia is
characterized by widespread generalized pain with an abnor-
mal nociceptive central processing [27, 28]. By contrast,
most clinicians being involved in the treatment of chronic
pain would argue that ﬁbromyalgia is not a purely central
neuropathic pain syndrome, as reviewed recently [29].
Therefore,weanalysedinthepresentsurveytheﬁbromyalgia
patients as independent group from patients diagnosed with
central neuropathic pain (see Table 3). Fibromyalgia was
diagnosed according to the criteria of the American College
ofRheumatology[30],includingtenderpointonthephysical
examination [31, 32]. All patients complained widespread
pain and revealed soreness upon pressure in at least 11 out
of 18 tender points.
3.2. Analgesic Medication and Its Eﬃcacy prior to Therapy.
Patients most commonly received nonopioids, such as
NSAID’s n = 60 (48%), COX2-inhibitors n = 34 (27%),
paracetamol n = 29 (23%), metamizol n = 44 (36%) (see
Table 2),butalsoopioids,tramadoln = 35(28%),morphine
n = 22 (18%), or hydromorphone n = 17 (14%), as well
as coanalgesics, such as antidepressants n = 68 (55%) or
anticonvulsants n = 40 (32%).
The eﬃcacy of the analgesic medication prior to delta 9-
THC treatment was assessed by the patients as follows: very
good n = 1 (0.8%), good n = 4 (3%), satisfactory n = 15
(12%), suﬃcient n = 24 (19%), insuﬃcient n = 58 (47%),
poor n = 20 (16%).
3.3. Analgesic Medication during Delta 9-THC Therapy. Dur-
ing therapy with delta 9-THC, administration of analgesics
could be reduced. Only nonopioids were maintained in 36
patients (29%), opioids continued in 39 patients (31%), and
coanalgesic medication pursued in 54 patients (43%) (see
Table 2).
3.4. Delta 9-THC Dose and Duration of Administration.
Delta 9-THC was administered as liquid (n = 78, 63%),
as capsule (n = 27, 22%), or both in combination (n =
19, 15%). On average, a mean daily dose below 7.5mg
delta 9-THC was administered to 47 patients (38%), dosages
between 7.5 and 15mg received 26 patients (21%), and
dosages >15mg were taken by 16 patients (13%). In 35
patients (28%) the daily taken delta 9-THC dose could not
be obtained. Overall, the median administered delta 9-THC
concentration was on average 7.5mg per day (interquartile
range 5–12.5mg).
35 patients received delta 9-THC medication up to 4
months (28%), 38 patients 4–24 months (31%), and 16
patients for more than 24 months (13%). No duration
recordings, however, were obtained from 35 patients (28%).
Thus, on average, delta 9-THC treatment lasted 217 days
(interquartile range 27–412 days).
3.5. Pain Score. Pain intensity was estimated on a verbal
rating scale (VRS), as described previously.
Prior to delta 9-THC administration, light pain was
recorded in n = 2 patients (2%), moderate pain in n = 7
(6%), intense pain in n = 24 (19%), very strong pain in
n = 71 (57%), and worst pain imaginable in n = 20 (16%)
(see Figure 1(a)). Following delta 9-THC administration,
verbally reported pain intensity improved signiﬁcantly (P<
.001, Pearson’s chi-square test), revealing a median value of
4 “moderate pain” after delta 9-THC in comparison to a
median value of 8 “very strong pain” prior to THC-therapy.
In particular, during delta 9-THC administration, no pain
was reported on the verbal rating scale in n = 4 patients
(3%), slight pain in n = 26 (21%), moderate pain in n = 57
(46%), intense pain in n = 28 (23%), very strong pain in
n = 8 (7%), and worst pain imaginable still in 1 patient (see
Figure 1(a)).
Subgroupanalysisofﬁbromyalgiarevealednodiﬀerences
of pain intensity to the group of inﬂammatory- and trauma-
evoked central neuropathic pain patients prior to and
during/after delta 9-THC medication. Prior to delta 9-THC
administration, mean pain intensity (VRS) of ﬁbromyalgia
was on average 7.9 ± 1.5, which was reduced to 4.4 ± 1.5
during/after THC-treatment. Similarly, inﬂammatory pain
patients reported a mean pain intensity of on average 7.6 ±
1.7 before THC, and 4.2 ± 1.9 after delta 9-THC therapy.
Trauma-inducedcentralneuropathicpainpatientsestimated
pain at 7.6 ± 1.4p r i o rt oa n d3 .8+1 .5 during/after delta 9-
THC medication (see Table 3).
Maximum perceived pain intensity was estimated on a
numeric rating scale (NRS), as described previously. Pain
reported by patients before THC-therapy was NRS < 6i n
n = 4( 3 % ) ,N R S6i nn = 3( 2 % ) ,N R S7i nn = 7( 6 % ) ,4 Anesthesiology Research and Practice
Table 2: Medication administered to the patients before and during/after delta 9-THC therapy. A substantial reduction of the medication
within each group, that is, nonopioids, opioids, or nonanalgesics (primarily antidepressants and anticonvulsants), could be recorded during
the treatment with delta 9-THC.
Before delta 9-THC therapy During/after delta 9-THC therapy
Comedication Number of patients % Number of patients %
Nonopioids
NSAID 60 48 7 5.6
COX2-inhibitors 34 27 7 5.6
Paracetamol 29 23 3 2.4
Metamizole 44 35 10 8.1
Flupirtin 37 30 7 5.6
others 14 11 2 1.6
Opioids
Tramadol 35 28 2 1.6
Naloxone 36 29 5 4
Buprenorphin/fentanyl 15 12 5 4
Morphin 22 18 7 5.6
Hydromorphone 17 14 10 8.1
Oxycodone 13 10 5 4
O t h e r s 655 4
Nonanalgesics
Antidepressants 68 55 18 14.5
Anticonvulsants 40 32 18 14.5
Corticosteroids 19 15 6 4.8
NMDA-antagonists 5 4 5 4
Others 21 17 7 5.6
Table 3: Estimated pain intensity (VRS) and maximum/minimum pain (NRS) recorded in the subgroups of “inﬂammatory central
neuropathy”—“central neuropathic pain due to trauma”—“ﬁbromyalgia” prior to and during/after delta 9-THC therapy. No signiﬁcant
diﬀerences between the groups could be analysed. In each group, delta 9-THC medication caused a noticeable amelioration of pain.
Inﬂammatory central neuropathy Central neuropathy due to trauma Fibromyalgia
Prior to After Prior to After Prior to After
Delta 9-THC medication Delta 9-THC medication Delta 9-THC medication
Pain intensity 7.6 ±1.74 .2 ±1.97 .6 ±1.43 .8 ±1.57 .9 ±1.54 .4 ±1.5
(VRS, 0–10)
Max. pain 7.6 ±1.74 .9 ±2.49 .3 ± 15 .3 ±1.79 .3 ±1.16 .1 ±2.1
(NRS, 0–10)
Min. pain 5.4 ±1.82 .1 ±1.56 .0 ± 12 .9 ±1.96 .6 ±23 .0 ±1.8
(NRS, 0–10)
NRS 8 in n = 17 (14%), NRS 9 in n = 19 (15%), and NRS 10
in n = 74 (60%). In contrast, maximum pain estimated by
the patients after delta 9-THC therapy was perceived at NRS
< 6i nn = 55 patients (44%), NRS 6 in n = 27 (22%), NRS
7i nn = 9( 7 % ) ,N R S8i nn = 23 (19%), NRS 9 in n = 1
(0.8%), and NRS 10 in n = 9 (7%) (see Figure 1(b)).
No signiﬁcant diﬀerence of maximum pain was obtained
between ﬁbromyalgia syndrome and inﬂammatory- or
trauma-evoked central neuropathic pain patients. On aver-
age, maximum pain intensity (NRS) was in ﬁbromyalgia
recorded at 9.3 ± 1.1 prior to delta 9-THC and 6.1 ±
2.1 thereafter. Central chronic pain patients reported a
maximum pain intensity of 8.7 ± 1.7 (inﬂammatory pain)
and 9.3+1 (trauma pain) prior to delta 9-THC, but 4.9+2.4
(inﬂammatory pain) and 5.3+1.7 (trauma pain) after THC-
therapy, respectively (see Table 3).
3.6. Psychometric Assessment. Prior to delta 9-THC admin-
istration, the Pain Disability Index (PDI) was on average
36.4 ± 10.7, which improved signiﬁcantly to 22.8 ± 10.8
with the delta 9-THC administration (P<. 001). Similarly,
improved Medical Outcomes Short-Form scores (SF-12)
were recorded, with signiﬁcantly increased health-related
subscale scores from 23.1 ± 6.3 before therapy to 33.4 ±
9.7 after delta 9-THC administration (P<. 001) and a
comparableincreaseofthementalsubscalescorefrom35.6±
9.1t o4 7 .3 ± 7.4( P<. 001), respectively. Quality of life
assessed by the pain summary scale (QLIP) also improved
by about 150% from 9.7+6 .6 before therapy to 24.7+6 .9
after delta 9-THC (see Figure 2). In addition, pain-related
disability of patients to perform their daily professional work
reduced from a mean score impairment of 7.6 ± 2.3p r i o rt o
therapyto5.2±2.7afterdelta9-THC.Finally,meanHospitalAnesthesiology Research and Practice 5
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Figure 1: Number of patients and their estimation of the perceived
pain intensity before (white bar) and during/after (black bar) delta
9-THC therapy by means of (a) Verbal Rating Scale (VRS) and (b)
Numeric Rating Scale (NRS). Values of the VRS indicate “no pain”
(0), “slight pain” (2), “moderate pain” (4), “intense pain” (6), “very
strong pain” (8), “worst pain imaginable (10). The endpoints of the
NRS indicate “no pain” (0) and “worst pain imaginable” (10).
Anxiety and Depression Scale (HADS) was attenuated for
anxiety from 10 ± 6.1t o5 .2 ± 3.6 and for depression from
13.3 ±5.5t o7 .3 ±4.1, respectively (P<. 001).
Thevastmajorityofpatients(92%)evaluatedthedelta9-
THC therapy as eﬃcient and accepted its administration as
coanalgesic.Incontrast,noimprovementwasreportedin3%
of the patients, and 5% complained of increased pain (data
not shown).
3.7.AdverseEﬀects. In12patients(10%),adverseeﬀectswere
reported but tolerated during delta 9-THC therapy, of which
tiredness (n = 3) and sedation or dizziness (n = 4) were
primary side eﬀects.
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Figure 2: Psychometric assessment of the patients before (white
bar) and during/after (black bar) delta 9-THC therapy. Particularly
Pain Disability Index (PDI), Quality of Life (QLIP), and Hospi-
tal Anxiety Depression Scale (HADS) improved signiﬁcantly in
response to delta 9-THC treatment.
4. Discussion
Cannabis (delta 9-THC) has been recognized as appetite
stimulant and antiemetic drug, and therefore had been
administered clinically to ameliorate side eﬀects in patients
receiving, for example, cancer- or HIV-chemotherapy [33,
34]. The therapeutic index of delta 9-THC, however, is
narrow. Therapeutic eﬃcient plasma THC-levels are often
accompanied by the typical cannabinoid side eﬀects and
these may be indicated in special populations, such as
chemotherapy-induced nausea or cachexia. By contrast,
possiblyduetothenarrowtherapeuticindex[15],conﬂicting
reports have emerged upon the clinical use of delta 9-THC
in diﬀerent areas of pain therapy [14] and cannabinoids
were acknowledged as coanalgesic adjunct rather than a
pure analgesic [21–23, 35]. Also, delta 9-THC should be
considered as a psychopharmacological analgesic medication
[20]; therefore a careful risk/beneﬁt analysis of cannabinoid
treatment may be required, including the evaluation of
misuse risk assessment of patients addiction behaviour [20]
and withdrawal strategies in cases misuse occur.
In the present retrospective survey we assessed delta 9-
THC therapy in central neuropathic pain and ﬁbromyalgia
patients. Even though it appears premature to classify
ﬁbromyalgia as a neuropathic pain syndrome [29], these
patients suﬀer chronic pain and often from an impaired
quality of life due to depression, sleep deprivation, or other
functional somatic syndromes. Therefore, these patients may
proﬁt from a coanalgesic and psychopharmacologic delta 9-
THC therapy. About 25% of patients, however, withdrew
from delta 9-THC administration for various reasons,
amongothersduetoaself-assessedineﬀectivetherapy.Those
patients who did respond to delta 9-THC therapy, the vast6 Anesthesiology Research and Practice
majority reported a signiﬁcant reduction of pain intensity,
a relevant improvement of mood and quality of life, and a
lowering of concomitant opioid medication.
4.1.PainIntensity. Inourpatientsample,THCtreatmentled
to a signiﬁcant reduction in pain intensity. Noteworthy, this
eﬀect could be observed when a mean daily dose of 7.5 mg
THC was administered. This dosage shows high acceptance
and eﬃcacy.
According to our ﬁndings, positive reports had been
reported previously in smaller patient samples in which
delta 9-THC was used for therapy of refractory neuropathic
pain states [16]. The authors described the combination of
cannabinol and cannabidiol being eﬀective in the treatment
of central neuropathic pain in multiple sclerosis patients. A
recent meta-analysis supported these ﬁndings [36]. In addi-
tion, other clinical trials in which central neuropathic pain
patients were treated with cannabinoids revealed a modest
but clinically relevant analgesic eﬀect in the treatment group
when compared to placebo [37, 38]. In addition, in the
present survey, patients reported that eﬃcacy and acceptance
of therapy were signiﬁcantly better during THC treatment. It
shouldbenotedthatacannabinoid-basedanalgesiaisnotfor
acute or subacute pain therapy. However, after a beneﬁcial
trial, THC may be considered as a longer term coanalgesic.
As reported previously after oromucosal cannabis-based
therapy of central neuropathic pain patients, the perceived
pain intensity was reduced and sleep disturbances improved
over a time period exceeding 1 year [39, 40].
No eﬀects of delta 9-THC, however, were observed
in postoperative pain management [41] and experimental
human pain models [23]. Also, a study conducted in
refractory central neuropathic pain patients did not support
an overall beneﬁt of THC on pain and quality of life upon
sublingual administration of the cannabinoid nabilone [42].
In this investigation, however, treatment was terminated in
5 out of 7 patients due to intolerable side eﬀects, probably
caused by the administered doses of up to 25mg/day. The
short period of drug administration in these studies may
explain a lack of analgesic eﬀect. If a single dose exceeds
20mg THC, side eﬀects are likely to dominate before the
appearanceofpharmacologicaleﬀects.THCislipophilic and
has a complex central pharmacokinetic with unexpectedly
long half life in the CNS. Therefore, as reported by Rog
and colleagues, an eﬃcient cannabinoid therapy may be
achieved by long-term administration of delta 9-THC at low
doses[39]toenableasteady-statetissueTHC-concentration,
which also would meet the narrow therapeutic range of THC
as a psychogenic drug.
4.2. Quality of Life. A further important and beneﬁcial
eﬀect of delta 9-THC therapy is the change of the patient’s
mood that can occur in addition to pain reduction. Ani-
mal data suggested an antidepressant eﬀect of THC [43,
44], which is supported by the present survey showing a
signiﬁcant reduction of depression in the patients during
treatment. This eﬀect likely is attributed to an activation
of cannabinoid receptors in the brain. In human neocortex
and amygdala, the CB1 receptor is frequently expressed. The
amygdala, the anterior cingulate cortex, and the prefrontal
cortex are key structures in the brain for memory, for
the perception and emotional processing of pain, and also
for the integration of mood modulation. In an animal
model, Marsicano et al. demonstrated that aversive memory
can be extinguished after application of THC [45]. Also,
in experimental catastrophic situations, THC was able to
diminish stress reaction in animals [43, 44]. Given that
pain memory is a crucial mechanism of maintaining pain
perception, these experimental data may be of importance to
explain the beneﬁcial eﬀect of delta 9-THC in the treatment
of chronic pain patients. The intake of antidepressants and
anticonvulsants in neuropathic pain states has been linked
to pain memory and mood changes. Their eﬀectiveness
apparently increased during THC-therapy, indicated by a
reduced administration. Thus, therapeutic eﬀects of delta
9-THC might be based, at least to some extent, on pain
memory extinction and mood changes.
Importantly, in this context, delta 9-THC treatment
additionally improved health-related quality of life, as
indicated here by the PDI and SF12 scores. Previous
data recorded in humans support this ﬁnding [2, 46].
Particularly, patients suﬀering multiple sclerosis [37]o rp a i n
from brachial plexus avulsion [46] appraise THC therapy
and report better quality of life. To assess the eﬀect of
therapeutic intervention, however, pain research has mainly
focused on the reduction of pain intensity, even though
quality of life parameters may reﬂect clinical improvement
for the patients much better. In this respect, ability to work
or job impairment is important factors. Here, we found
that work-related situations improved after THC treatment.
Data on this topic with respect to central neuropathic
pain and ﬁbromyalgia are missing so far, as most studies
investigating environmental aspects improving work-life
refer to musculoskeletal pain [47].
4.3. Concomitant Medication. Administration of delta 9-
THC supplemental to the current pain medication did not
deteriorate therapy; rather patients were able to reduce the
analgesics, particularly the intake of opioids. An interaction
between cannabinoids and opioids has been reported in pre-
vious experimental studies before and it was suggested that
delta 9-THC induced eﬀects are mediated also through delta
and kappa opioid receptors [48]. Interestingly, a reciprocal
alteration of receptor density has been observed in presence
of cannabinoids and opioids [49]. This observation also may
include modiﬁed receptor activation, for instance, delta 9-
THC enhanced opioid receptor recruitment, which would
explain a reduced opioid medication. Thus, as suggested
recently [50], drug combinations should be considered for
therapy, and as presented here, delta 9-THC may represent
one option of medication.
Intriguingly, of the concomitantly administered medi-
cation, no change in the use of NMDA antagonists was
recorded. This observation might be attributed to a lacking
additional eﬀect of cannabinoids with NMDA antagonists.
Also, an inhibitory action of selective NMDA antagonists
on the antinociceptive eﬃcacy of cannabinoids was reportedAnesthesiology Research and Practice 7
recently in the rat periaqueductal grey [51], which may
require an increased cannabinoid administration rather than
a reduced NMDA antagonist medication for therapy.
4.4. Limitations. A limitation of the study is performance of
a single telephone survey by one interviewer. A face-to-face
serial interviews may be suggested as a better study design
alternative, which was considered during development of
the study protocol. Performing a multicenter study would
require a large number of interviewers conducting the face-
to-face interview. The parameter assessment by diﬀerent
interviewers may cause variations, particularly considering
psychometric parameters, and irrespective the experiences
of the interviewers. A telephone survey, performed by one
interviewer only, may be minimally inﬂuenced by external
factors and therefore suggests consictency of the evaluated
parameters in the patient.
Another limitation may be due to the heterogenous
patient group with very little selection criteria. This justiﬁ-
able concern actually was one objective of the survey, that is,
to explore the applicability and usefulness of an additional
coanalgesic cannabinoid treatment in a broad and unspeciﬁc
groupofpainpatients.Consequently,therelativelyhighdrop
out rate of about 25% may be due to the virtually absent
selection criteria of the patients, but also may have caused
by the narrow therapeutic index of THC, as mentioned
previously.
Amelioration of pain and quality of life improvement
weremajoroutcomeparameters.Infuturesurveys,therefore,
further limiting factors like practice variation, duration of
medication, assessment of addiction behaviour, and misuse
risk should be considered and included in future interview
protocols.
5. Conclusions
Patients taking delta 9-THC for pain therapy can be inter-
viewed easily by phone to explore their tolerance towards
the medication. Some but not all patients who respond and
tolerate delta 9-THC administration may beneﬁt consider-
ably from this coanalgesic. Acceptance and tolerance of a
short-lasting delta 9-THC trial therefore would determine
a selection criterion for an additional treatment option to
reduce pain, to decrease the comedication, and to improve
quality of life. Transient delta 9-THC titration up to about
15mg, its continued administration for a few weeks, the
documentation of the patients tolerance to the therapy
with putative side eﬀects, and the recording of the patients’
self-reported pain estimates would reveal the eﬃcacy and
tolerabilityofasupplementalcannabinoid-basedcoanalgesic
medication.
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